Neuropathic Pain - Pipeline Review, H2 2016 - Comparative Analysis at Various Stages - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Neuropathic Pain - Pipeline Review, H2 2016" report to their offering.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • AnaBios Corp
  • Anavex Life Sciences Corp
  • AngioChem Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • BCI Pharma
  • Biogen Inc
  • Hydra Biosciences Inc
  • Immune Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Nhwa Pharmaceutical Corp Ltd
  • Johnson & Johnson
  • Pfizer Inc
  • Pharmaleads SA
  • PharmEste Srl
  • Phosphagenics Ltd
  • Prismic Pharmaceuticals Inc
  • RaQualia Pharma Inc
  • Re-Pharm Ltd
  • Relmada Therapeutics Inc
  • Revance Therapeutics Inc
  • Saniona AB
  • (80+ More)

Key Topics Covered:

  1. Introduction
  2. Neuropathic Pain Overview
  3. Therapeutics Development
  4. Pipeline Products for Neuropathic Pain - Overview
  5. Pipeline Products for Neuropathic Pain - Comparative Analysis
  6. Neuropathic Pain - Therapeutics under Development by Companies
  7. Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
  8. Neuropathic Pain - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Neuropathic Pain - Products under Development by Companies
  13. Neuropathic Pain - Products under Investigation by Universities/Institutes
  14. Neuropathic Pain - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/8qw3fn/neuropathic_pain

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Analgesics

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs , Analgesics